ACUT Overview

Event Announcement: The Life Science Virtual Investor Forum is scheduled for September 18, 2025, co-hosted by Zacks SCR, inviting individual and institutional investors to attend presentations and one-on-one meetings with company management.

Participation Details: Investors are encouraged to pre-register and perform an online system check for a smoother experience, with no cost to attend live presentations or schedule meetings.

AccuStem Presentation Announcement: AccuStem Sciences, Inc. will have its CEO, Wendy Blosser, present at the Life Sciences Virtual Investor Forum on September 18, 2025, discussing the company's innovative cancer diagnostics and their potential value to investors.

Event Details and Participation: The event will allow real-time questions from investors, with an archived webcast available afterward. Investors are encouraged to pre-register and check the online system for a smoother experience.

Chairman's Share Purchase: Gabriele Cerrone, Chairman of AccuStem Sciences, has acquired an additional 8,991 shares, increasing his total holdings to 6,500,000 shares.

Company Overview: AccuStem is focused on improving cancer patient outcomes through innovative molecular testing that addresses clinical needs from screening to treatment and monitoring.

Partnership Expansion: AccuStem Sciences and EmeritusDX are expanding their partnership to commercialize the MSC test for lung cancer screening, which analyzes microRNAs to improve lung nodule stratification and patient outcomes.

Future Plans: The MSC test is set to launch in US clinics in 2026, with both companies working on reimbursement strategies to increase access for the 1.6 million patients diagnosed with lung nodules annually.

Company Update: AccuStem Sciences, Inc. announced that its Chairman, Gabriele Cerrone, has purchased an additional 5,000 shares, increasing his total holdings to 4,915,759 shares.

Company Mission: AccuStem is focused on improving cancer patient outcomes through innovative molecular testing and understanding tumor biology to enhance clinical decision-making.

Chairman's Share Purchase: Gabriele Cerrone, Chairman of AccuStem Sciences, has acquired an additional 152,802 shares, increasing his total holdings to 4,872,759 shares.

Company Overview: AccuStem is focused on improving cancer patient outcomes through innovative molecular testing that addresses unmet clinical needs in cancer screening, treatment, and monitoring.